Connect with us

Business

Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency – Yahoo Finance

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in a Phase 2 proof-of-concept study, VX-864 achieved…

Published

on

Article feature image
ADVERTISEMENT

– Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated –
– Results provide proof-of-mechanism, although magnitude of treatment effect observed…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Twitter CEO Jack Dorsey Reveals Surprise Bitcoin Plan After Elon Musk Sparked Crypto Price Chaos With Ethereum And Dogecoin Support – Forbes
Article feature image
Hawaii reports 104 new COVID cases; no additional fatalities – Hawaii News Now
Article feature image
I just boarded the first Royal Caribbean cruise in North America in more than a year; here’s what it was like – The Points Guy